Immunocore Holdings plc (IMCR) financials: revenue, earnings and cash flow
Fiscal 2018–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Immunocore Holdings’s revenue went from $30M in fiscal 2018 to $400M in fiscal 2025, growth of about 44.6% a year.
Net income in fiscal 2025 was -$36M, a net margin of -8.9%; the highest of the period.
Over the twelve months to September 30, 2026, revenue was $429M and net income -$32M.
Free cash flow was -$15M in fiscal 2025 and positive in 1 of the 8 years shown.
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $429M | $400M | $310M | $249M | $174M | $36M | $41M | $34M | $30M |
| Gross profit | — | $395M | $307M | $248M | $173M | $36M | $41M | — | — |
| Operating income | — | -$45M | -$70M | -$60M | -$52M | -$175M | -$118M | -$156M | -$120M |
| Net income | -$32M | -$36M | -$51M | -$55M | -$53M | -$180M | -$101M | -$137M | -$92M |
| EPS (diluted) | $-0.63 | $-0.69 | $-0.99 | $-1.07 | $-1.02 | $-3.48 | $-1.96 | $-2.66 | $-1.77 |
| R&D | — | $275M | $222M | $164M | $102M | $100M | — | — | — |
| Revenue growth | — | +28.9% | +24.4% | +43.0% | +377.9% | −11.2% | +21.3% | +11.9% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10M | -$11M | $26M | $3M | -$49M | -$143M | -$84M | -$136M | -$21M |
| Capital spending | -$8M | -$4M | -$5M | -$5M | -$2M | -$1M | -$4M | -$5M | -$4M |
| Free cash flow | -$18M | -$15M | $21M | -$2M | -$51M | -$144M | -$88M | -$141M | -$26M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — | — | — |
| Stock-based pay | — | $38M | $34M | $32M | $33M | $49M | $11M | $4M | $852480 |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $864M | $820M | $443M | $402M | $321M | $177M | $98M | $159M |
| Debt | — | $44M | $42M | $36M | $81M | $50M | $50M | $25M | — |
| Equity | — | $381M | $361M | $369M | $339M | $234M | $77M | $20M | $72M |
| Total assets | — | $1.1B | $1.0B | $597M | $527M | $407M | $269M | $245M | — |
| Shares (diluted) | 51M | 52M | 52M | 52M | 52M | 52M | 52M | 52M | 52M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | 98.7% | 99.1% | 99.6% | 99.4% | 100.0% | 100.0% | — | — |
| Operating margin | — | -11.3% | -22.7% | -23.9% | -29.7% | -478.5% | -286.2% | -460.9% | -395.1% |
| Net margin | -7.5% | -8.9% | -16.5% | -22.2% | -30.1% | -493.4% | -246.0% | -404.9% | -302.8% |
| FCF margin | -4.2% | -3.8% | 6.7% | -1.0% | -29.5% | -396.0% | -213.6% | -416.8% | -85.0% |
| ROIC | — | -8.4% | -16.9% | -13.4% | -9.7% | -48.6% | -78.6% | -287.2% | -134.2% |
| ROE | — | -9.3% | -14.2% | -15.0% | -15.5% | -77.0% | -131.5% | -703.6% | -126.6% |
Frequently asked questions
What is Immunocore Holdings’s annual revenue?
$400M in fiscal 2025 and $429M over the twelve months to September 30, 2026.
How much profit does Immunocore Holdings make?
Net income was -$36M in fiscal 2025 (net margin -8.9%).
Is Immunocore Holdings’s revenue growing?
Yes: revenue rose 29.0% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.